Moreover, the combination of AZD5363 with hormonal therapy improved efficacy of PI3K/AKT-targeted treatment in PTEN-negative prostate carcinoma models, implicating this pharmacological strategy in this type of cancer [129]. Here, PIK3CD is linked to cancer.